LIP
IMVT icon

Lighthouse Investment Partners’s Immunovant IMVT Stock Holding History

Lighthouse Investment Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-86,180
Closed -$3.63M – 423
2023
Q4 		$3.63M Buy
+86,180
New +$3.17M 0.16% 137

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Lighthouse Investment Partners's IMVT Position: Q1 2024 in Review

Lighthouse Investment Partners sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 86,180 shares — an estimated $3.63M sold.

Lighthouse Investment Partners first reported a position in IMVT in Q4 2023 and held it in 1 quarter. The position peaked at $3.63M in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Lighthouse Investment Partners reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Lighthouse Investment Partners sold 86,180 Immunovant shares in Q1 2024, an estimated $3.63M.
  • Lighthouse Investment Partners first reported a position in Immunovant in Q4 2023 and held it in 1 quarter.
  • Lighthouse Investment Partners's Immunovant position peaked at $3.63M in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Lighthouse Investment Partners's 13F filing for Q1 2024, filed 13 May 2024.